Kantar Health Blog

  • Triumph in Breast Cancer: KuDOS to Lynparza

    by Stephanie Hawthorne | Jun 4, 2017
    Stephanie Hawthorne
    ASCO Annual Meeting 2017 - In the Plenary session, late breaking results from the Phase III OLYMPIAD trial, which evaluated Lynparza in comparison to “physician’s choice” chemotherapy (capecitabine, vinorelbine, eribulin) in 302 metastatic HER2- breast cancer patients with deleterious or suspected gBRCA mutations were presented. These results represent the first positive Phase III trial for a PARP inhibitor in breast cancer and the discussant, Dr. Allison Kurian, had an overall positive outlook stating that these results ”are practice-changing.”
    Continue Reading > | Go comment! | Share
  • Opdivo Making Strides in Advanced Hepatocellular Carcinoma

    by Stephanie Hawthorne | Jan 23, 2017
    Stephanie Hawthorne
    Oncology Conference Insight: ASCO GI 2017 --- It is an exciting time for patients and their doctors fighting advanced hepatocellular carcinoma (HCC). In mid-2016 the HCC community witnessed the first randomized trial to successfully improve survival outcomes in Nexavar® (sorafenib, Onyx/Amgen/Bayer)-pretreated HCC when the multikinase inhibitor Stivarga® (regorafenib, Bayer) demonstrated a 38% reduction in the risk of death compared with placebo in the Phase III RESOURCE trial.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ESMO 2016 --- A biologics license application for Tecentriq was accepted with priority review by the FDA in April 2016 for the treatment of patients with PD-L1-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who have progressed on or after platinum-containing chemotherapy, an indication in which Tecentriq also has Breakthrough Therapy Designation.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ESMO 2016 --- Immunotherapies have justifiably generated a lot of buzz in 2016. For lung cancer, much has changed in the past year. U.S. and European agencies approved Keytruda® (pembrolizumab, MSD) for second-line therapy in all histologies of PD-L1+ patients as well as Opdivo® (nivolumab, Bristol-Myers Squibb/Ono Pharmaceuticals) for use in second-line patients with all histologies.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ESMO 2016 --- Approximately three-quarters of breast cancers are hormone receptor-positive (HR+) and thus express estrogen receptors, progesterone receptors or both. Endocrine therapy is the mainstay of therapy for patients with HR+ and human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
    Continue Reading > | Go comment! | Share